Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient chinese herbal formula tested for rare muscle disease

NCT ID NCT07472777

Disease control Sponsor: Beijing University of Chinese Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a modified traditional Chinese herbal formula, Guilu Erxian Glue, can help people with myasthenia gravis (a disease causing muscle weakness). Researchers reviewed medical records of 231 patients who took the herbal formula alongside standard Western medicine. They measured how many patients had a relapse and how quickly they could reduce their regular medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Modified Guilu Erxian Glue (traditional Chinese herbal formula)
What this could lead to
If effective, this herbal formula could help control myasthenia gravis symptoms and reduce recurrence when added to standard Western medicine.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be biased. The herbal formula's benefits are uncertain and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

231 people

The number who actually took part.

Started

Jan 2024

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

MG patients

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically confirmed diagnosis of myasthenia gravis (MG), with other differential diagnoses excluded * Received standardized conventional Western medicine treatment for MG for at least 1 month (bromopyridostigmine tablets combined with prednisone acetate tablets) * Complete and traceable medical records available for the entire study period Exclusion Criteria: * Complicated with other major systemic diseases, severe functional impairment of the heart, liver or kidney, or a documented history of mental illness * Incomplete medical records that cannot support full data extraction and statistical analysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis (MG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis (MG)

Contacts and locations

Locations

  • The First Affiliated Hospital of Henan University of Chinese Medicine

    Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.